IP Verse

Olswang competitive analysis

Explore patent oppositions filed by Olswang against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jul 23, 2026

Patent Number	Title	Applicant	Opposition Date
EP3770258	Modulation Of Ube3A-Ats Expression	BAYLOR COLLEGE OF MEDICINE	Apr 16, 2025
EP3628319	Methods Of Treating Hepatic Encephalopathy Using Rifaximin	SALIX PHARMACEUTICALS	Nov 14, 2024
EP3542790	Compositions Comprising A Delivery Agent And Preparation Thereof	NOVO NORDISK	Jun 13, 2024
EP3636778	Agents For Use In Treating Facioscapulohumeral Dystrophy (Fshd)	FRED HUTCHINSON CANCER CENTER	Oct 12, 2022
EP2863895	Tablet Formulation Comprising A Peptide And A Delivery Agent	NOVO NORDISK	Jan 14, 2022
EP2350096	Methods Of Treating Hepatic Encephalopathy	SALIX PHARMACEUTICALS	Aug 6, 2020
EP3149481	Multiplex Assay For Improved Scoring Of Tumor Tissues Stained For Pd-L1	VENTANA MEDICAL SYSTEMS	Oct 9, 2019
EP2827845	Compositions Comprising A Delivery Agent And Preparation Thereof	NOVO NORDISK	Sep 26, 2019
EP3111221	Methods, Kits, And Systems For Scoring The Immune Response To Cancer By Simultaneous Detection Of Cd3, Cd8, Cd20 And Foxp3	VENTANA MEDICAL SYSTEMS	Jul 10, 2019
EP3009143	Progranulin For Use In Treating Parkinson'S Disease Or Alzheimer'S Disease	NEURODYN LIFE SCIENCES	Jul 3, 2019

Discover the latest PTAB cases involving Olswang, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Olswang with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jul 23, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
CMS CAMERON MCKENNA NABARRO OLSWANG	11	-	-	-
NOVO NORDISK	9	128	1	9
SALIX PHARMACEUTICALS	-	19	-	3
VENTANA MEDICAL SYSTEMS	-	3	-	-